Compare ACADIA Pharmaceuticals Inc. (ACAD) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs General Mills, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.46 (market cap $5.07B), while General Mills, Inc. trades at $37.4 (market cap $20.24B). The key difference: General Mills, Inc. is far larger — about 4× ACADIA Pharmaceuticals Inc.'s market cap, and General Mills, Inc. pays a 6.43% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GIS | |
|---|---|---|
Market Cap | $5.07B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $51.11 |
52-Week Low | $20.06 | $32.17 |
Enterprise Value | $4.19B | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.
Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
